Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19-Reference-Cited by-同舟云学术

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Published:2022-09 Issue: Volume:122 Page:585-592
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Isa Flonza,Forleo-Neto Eduardo,Meyer Jonathan^ORCID,Zheng Wenjun,Rasmussen Scott,Armas Danielle,Oshita Masaru,Brinson Cynthia,Folkerth Steven,Faria Lori,Heirman Ingeborg,Sarkar Neena,Musser Bret J.^ORCID,Bansal Shikha,O'Brien Meagan P.,Turner Kenneth C.,Ganguly Samit^ORCID,Mahmood Adnan,Dupljak Ajla,Hooper Andrea T.,Hamilton Jennifer D.^ORCID,Kim Yunji,Kowal Bari,Soo Yuhwen,Geba Gregory P.,Lipsich Leah,Braunstein Ned,Yancopoulos George D.,Weinreich David M.,Herman Gary A.

Funder

Regeneron Pharmaceuticals

F Hoffmann-La Roche Ltd

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference35 articles.

1. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with;Avanzato;Cell,2020

2. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N Engl J Med,2021

3. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies;Baum;Science,2020